SCHEMBL12798481

SCHEMBL12798481

Cc1ccc(N2CCN(c3cc(C(=O)O)ccc3C)C2=O)cc1

nearest known ligand 0.60

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
GAA P10253 1/20 0.50
MEN1 O00255 1/20 0.46
KMT2A Q03164 1/20 0.46
TTR P02766 1/20 0.45
NPSR1 Q6W5P4 1/20 0.45
BRD4 O60885 1/20 0.45
BRD2 P25440 1/20 0.45
BRD3 Q15059 1/20 0.45
CA12 O43570 1/20 0.44
CA1 P00915 1/20 0.44
CA9 Q16790 1/20 0.44
SMN1; SMN2 Q16637 2/20 0.43
CYP3A4 P08684 1/20 0.43
CYP2C9 P11712 1/20 0.43
SRD5A2 P31213 1/20 0.42
ALDH1A1 P00352 2/20 0.42
HTR7 P34969 1/20 0.42
HSD17B10 Q99714 1/20 0.42
HTT P42858 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL133885 0.86 HDAC1 (0.47) GAATTRBRD4BRD2BRD3
SCHEMBL17918391 0.86 GAA (0.45) GAAMEN1KMT2ATTRNPSR1
SCHEMBL172629 0.81 ALDH1A1 (0.57) GAAMEN1KMT2ATTRCYP3A4
SCHEMBL3782553 0.76 HDAC1 (0.48) ALDH1A1
SCHEMBL12798465 0.74 TTR (0.46) TTRBRD4BRD2BRD3CA12
SCHEMBL171164 0.72 TTR (0.49) TTRBRD4BRD2BRD3CA12
SCHEMBL29606903 0.71 DDB1 (0.58) GAATTRSMN1; SMN2CYP3A4CYP2C9
SCHEMBL21409149 0.71 DDB1 (0.58) GAATTRSMN1; SMN2CYP3A4CYP2C9
SCHEMBL135095 0.71 ALDH1A1 (0.52) GAAMEN1KMT2ATTRCYP3A4
SCHEMBL6575696 0.71 RARB (0.46) NPSR1SMN1; SMN2CYP3A4ALDH1A1HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7902241-B2 3-[3-(4-ISOPROPYLPHENYL)-2,5-DIOXO-IMIDAZOLIDIN-1-YL]- or 2-OXO-2,3-DIHYDROIMIDAZOL-1-YL]BENZOIC ACID; modulating premature translation termination and nonsense-mediated mRNA decay; gene therapy; cystic fibrosis or Duchenne muscular dystrophy; cancer, autoimmune disease, blood disease, diabetes PTC THERAPEUTICS, INC. (US) 2011-03-08 US disclosed
US-20080275233-A1 UREIDO SUBSTITUTED BENZOIC ACID COMPOUNDS AND THEIR USE FOR NONSENSE SUPPRESSION AND THE TREATMENT OF DISEASE PTC THERAPEUTICS, INC. 2008-11-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080275233-A1 UREIDO SUBSTITUTED BENZOIC ACID COMPOUNDS AND THEIR USE FOR NONSENSE SUPPRESSION AND THE TREATMENT OF DISEASE UPF1, VHL, URB2 GAA 275/4885MEN1 2666/4885KMT2A 1499/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.